ATG 201
Alternative Names: ATG-201Latest Information Update: 10 Oct 2024
At a glance
- Originator Antengene Corporation
- Class Bispecific antibodies; Immunoglobulin Fv fragments; Recombinant fusion proteins
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Autoimmune disorders
Most Recent Events
- 10 Oct 2024 Antengene Corporation announces intention to submit IND for Autoimmune disorders in third quarter of 2025 (Antengene Corporation pipeline, August 2024)
- 26 Aug 2024 Preclinical trials in Autoimmune disorders in China (Parenteral) prior to August 2024